---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-21-009799"
form_type: "8-K"
ticker: "GTHP"
cik: "0000924515"
company_name: "GUIDED THERAPEUTICS INC"
filed_at: "2021-09-07T23:59:59+00:00"
generated_at: "2026-06-29T05:42:06.303276+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Guided Therapeutics passes regulatory review in China; receives $133K payment from SMI

## Summary
- Clinical trial at Fudan University approved; trials at 4 centers start Q3 2021.
- SMI paid $133,000 first installment; total $510,635 due during study.
- Expected payments up to $3M by end 2022 if NMPA approval granted.
- Minimum orders of $72M over 4 years post Chinese FDA approval.
- LuViva disposable royalty set at $1.90 per unit, adjusted for inflation.

## SEC filing metadata
- accession: 0001654954-21-009799
- form_type: 8-K
- ticker: GTHP
- cik: 0000924515
- company_name: GUIDED THERAPEUTICS INC
- filed_at: 2021-09-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/924515/000165495421009799/0001654954-21-009799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/924515/000165495421009799/gthp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-21-009799
- JSON: https://secwatch.observer/filing/0001654954-21-009799.json
- Plain text: https://secwatch.observer/filing/0001654954-21-009799.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.